Correspondence
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Endophthalmitis: Then and Now.
Relhan N, Forster R, Flynn Jr H Am J Ophthalmol. 2017; 187:xx-xxvii.
PMID: 29217351 PMC: 5873969. DOI: 10.1016/j.ajo.2017.11.021.
References
1.
Rayess N, Rahimy E, Storey P, Shah C, Wolfe J, Chen E
. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol. 2016; 165:88-93.
DOI: 10.1016/j.ajo.2016.02.028.
View
2.
Nentwich M, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H
. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina. 2013; 34(5):943-50.
DOI: 10.1097/IAE.0000000000000011.
View
3.
Sigford D, Reddy S, Mollineaux C, Schaal S
. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol. 2015; 9:773-81.
PMC: 4427080.
DOI: 10.2147/OPTH.S77067.
View
4.
Gregori N, Flynn Jr H, Schwartz S, Rosenfeld P, Vaziri K, Moshfeghi A
. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(6):643-8.
DOI: 10.3928/23258160-20150610-08.
View
5.
Brynskov T, Kemp H, Sorensen T
. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2013; 34(5):951-7.
DOI: 10.1097/IAE.0000000000000071.
View